Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Records the largest number of videos of people saying the same sentence uploaded to Facebook in one hour to raise awareness on Iron Deficiency Anaemia
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
The Omicron variant doesn't escape RTPCR and RAT; States advised to ramp up testing for prompt and early identification of any cases
Share of government health expenditure in total health expenditure increases to 40.8% (2017-18) from 28.6% (2013-14)
The company has has 10 existing labs in India
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Subscribe To Our Newsletter & Stay Updated